Posted by Michael Wonder on 21 Dec 2019
Bristol-Myers Squibb receives European Commission approval for Revlimid (lenalidomide) in combination with rituximab for the treatment of adult patients with previously treated follicular lymphoma
20 December 2019 - Revlimid plus rituximab is the first chemotherapy-free combination regimen approved in Europe for patients with follicular lymphoma who have relapsed or did not respond to previous treatment.
Bristol-Myers Squibb today announced that the European Commission has approved a new indication for Revlimid (lenalidomide), in combination with rituximab (anti-CD20 antibody), for the treatment of adult patients with previously treated follicular lymphoma (Grade 1-3a).
“This approval is a significant milestone for patients with follicular lymphoma whose disease is not responding to current therapy or has returned following prior treatment. In the phase 3 AUGMENT sudy, patients receiving R2 experienced extended periods of disease remission versus patients receiving rituximab plus placebo,” said Nadim Ahmed, President of Hematology at Bristol-Myers Squibb.
